+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 19Years +
All Genders
ID06135896

Phase 2 Study of Tripegfilgrastim to Lower Severe Neutropenia Risk in Adults With Unresectable Pancreaticobiliary Cancer Receiving Nal-IRI5-FULV Chemotherapy A Randomized, Open-Label Multicenter Trial

Led by National Cancer Center, Korea · Updated on 2025-06-18

98

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the effects of tripegfilgrastim on preventing severe neutropenia in patients with unresectable pancreaticobiliary cancers receiving nal-IRI5-FULV combination chemotherapy. Pancreatic and bile duct cancers have poor survival rates, especially when unresectable, and this study explores the potential benefit of using a pegylated granulocyte colony-stimulating factor G-CSF to reduce complications like neutropenia, which can occur during chemotherapy. The study is a phase 2, randomized controlled trial conducted at multiple centers. Participants will be randomly assigned to receive either the experimental treatment including tripegfilgrastim or a control regimen without it. Both groups receive chemotherapy every two weeks with premedications and infusions of Onivyde, leucovorin, and 5-FU. In the experimental group, tripegfilgrastim 6 mg is given subcutaneously 24 hours after completing 5-FU infusion to help reduce neutropenia risk. The control group receives the same chemotherapy but tripegfilgrastim is only given if febrile neutropenia occurs, with treatment paused until recovery. Participants will be followed through the intervention period until disease progression or unacceptable toxicity, with survival assessed every two months. Researchers will monitor neutropenia incidence, febrile neutropenia, emergency visits, overall survival, progression-free survival, and biomarkers for about one year. The total study duration extends until June 2026, including follow-up and statistical analysis periods. Safety and treatment effects will be carefully evaluated throughout the study.

CONDITIONS

Brief Title

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Research Team

S

Sangmyung Woo, M.D

J

Jung Won Chun, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here